.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,732,693

« Back to Dashboard
Patent 5,732,693 protects INOMAX and is included in one NDA. There has been one Paragraph IV challenge on INOmax.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 5,732,693

Title: Pause control of nitric oxide therapy
Abstract:A system for the delivery of nitric oxide therapy to a patient that allows interventions by a user by activating a pause mode through a user input. A CPU in the system recognizes the activation of the pause mode and sends a signal to close a valve in order to discontinue the supply of nitric oxide to the patient. The activation of the pause mode also deactivates the normal alarm systems. A timer is activated when the system enters the pause mode and the timer allows a predetermined amount of time to pass while the pause mode is in effect. After that predetermined period of time has elapsed, the timer causes the CPU to reopen the valve to reestablish the flow of nitric oxide for the continued therapy and reestablish the alarm systems. The pause mode can be thus carried out without changing any alarm settings, established flows and the like so that the therapy is again recommenced at the same conditions as were in effect prior to the initiation of the pause mode.
Inventor(s): Bathe; Duncan P. L. (Madison, WI), Kohlmann; Thomas S. (McFarland, WI), Tham; Robert Q. (Madison, WI)
Assignee: Ohmeda Inc. (Liberty Corner, NJ)
Application Number:08/766,833
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 1st percentile
Forward Citations: 4th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mallinckrodt Hosp
INOMAX
nitric oxide
GAS;INHALATION020845-002Dec 23, 1999DISCNNo5,732,693*PED► subscribeY
Mallinckrodt Hosp
INOMAX
nitric oxide
GAS;INHALATION020845-003Dec 23, 1999RXYes5,732,693*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc